Fig. 4: AC484 inflames the TME.
From: The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
a, Immunofluorescence (IF) microscopy of representative formalin-fixed paraffin-embedded tumour sections from B16 untreated, anti-PD-1-treated or AC484-treated tumours. Staining: DAPI, blue; CD45, green; CD8, red. b, Quantification of CD45+ (left) and CD8+ (right) cells from B16 tumours from a. c, Uniform manifold approximation and projection (UMAP) of 68,060 cells and 21 distinct clusters identified among CD45+-enriched immune cells (left). Cell density projections by condition (right). DCs, dendritic cells; Fbr., fibroblasts; Inflamm., inflammatory; Ma, macrophage; Mig. DCs, migratory DCs; Mo, monocyte; Mo-DCs, monocyte-derived DCs; Neut., neutrophil; pDCs, plasmacytoid DCs. d, Box plots of proportional changes by cluster of CD45+-enriched immune cells by treatment. e, Ratio of cells belonging to lymphoid-derived clusters versus myeloid-derived clusters by condition. f, Directional ratio of cells belonging to clusters identified as M1 macrophages versus M2 macrophages by condition.
